Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.64 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.56 |
| ▸ | CDK1 | P06493 | 3/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.51 |
| ▸ | CDK2 | P24941 | 2/20 | 0.51 |
| ▸ | CDK7 | P50613 | 2/20 | 0.51 |
| ▸ | CDK9 | P50750 | 2/20 | 0.51 |
| ▸ | CCNH | P51946 | 2/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | PLK4 | O00444 | 2/20 | 0.48 |
| ▸ | CDC7 | O00311 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 5/20 | 0.48 |
| ▸ | CA2 | P00918 | 5/20 | 0.48 |
| ▸ | CA9 | Q16790 | 5/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.45 |
| ▸ | PAK4 | O96013 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13896206 | 0.91 | CCNT1 (0.58) | KDRCDK1CCNT1CCNB1CDK2 | |
| SCHEMBL13896209 | 0.87 | MKNK1 (0.67) | KDRMKNK1CDK2EGFRPLK4 | |
| SCHEMBL13896208 | 0.86 | PLK4 (0.57) | KDRCDK1CCNT1CCNB1CDK2 | |
| SCHEMBL4266513 | 0.86 | PLK4 (0.57) | KDRCDK1CCNT1CCNB1CDK2 | |
| SCHEMBL4797977 | 0.84 | KDR (0.58) | KDRMKNK1CDK1CCNT1CCNB1 | |
| SCHEMBL4259513 | 0.83 | EGFR (0.49) | KDRMKNK1CDK2EGFRPLK4 | |
| SCHEMBL13896563 | 0.83 | MKNK1 (0.58) | KDRMKNK1CDK7CDK9CDK5 | |
| SCHEMBL13896212 | 0.82 | TNNI3K (0.55) | KDRMKNK1CDK1CCNT1CCNB1 | |
| SCHEMBL3283879 | 0.81 | KDR (0.50) | KDRCDK1CCNT1CCNB1CDK2 | |
| SCHEMBL10242647 | 0.81 | SYK (0.67) | KDRCDK1CCNT1CCNB1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314234-B2 | Bicyclic pyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-11-20 | — | — | US | claimed |
| US-20090076037-A1 | BICYCLIC PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | claimed |
| WO-2008039359-A2 | BICYCLIC PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-03 | — | — | WO | claimed |
| US-8314234-B2 | Bicyclic pyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-11-20 | — | — | US | disclosed |
| US-8314234-B2 | Bicyclic pyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-11-20 | — | — | US | disclosed |
| US-8314234-B2 | Bicyclic pyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-11-20 | — | — | US | disclosed |
| US-20090076037-A1 | BICYCLIC PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076037-A1 | BICYCLIC PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076037-A1 | BICYCLIC PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | disclosed |
| WO-2008039359-A2 | BICYCLIC PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008039359-A2 | BICYCLIC PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076037-A1 | BICYCLIC PYRIMIDINE KINASE INHIBITORS | DCK, CDK2, DTYMK | KDR 1646/4885MKNK1 135/4885CDK1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.